Cargando…

Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of Mycoplasma synoviae isolates

Mycoplasma synoviae infection occurs worldwide, leading to considerable economic losses in the chicken and turkey industry due to infectious synovitis, respiratory diseases and eggshell apex abnormalities. Control programs against M. synoviae infection are based on eradication, vaccination and medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekő, Katinka, Kreizinger, Zsuzsa, Yvon, Cécile, Saller, Orsolya, Catania, Salvatore, Feberwee, Anneke, Gyuranecz, Miklós
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598480/
https://www.ncbi.nlm.nih.gov/pubmed/33125410
http://dx.doi.org/10.1371/journal.pone.0241647
_version_ 1783602622050074624
author Bekő, Katinka
Kreizinger, Zsuzsa
Yvon, Cécile
Saller, Orsolya
Catania, Salvatore
Feberwee, Anneke
Gyuranecz, Miklós
author_facet Bekő, Katinka
Kreizinger, Zsuzsa
Yvon, Cécile
Saller, Orsolya
Catania, Salvatore
Feberwee, Anneke
Gyuranecz, Miklós
author_sort Bekő, Katinka
collection PubMed
description Mycoplasma synoviae infection occurs worldwide, leading to considerable economic losses in the chicken and turkey industry due to infectious synovitis, respiratory diseases and eggshell apex abnormalities. Control programs against M. synoviae infection are based on eradication, vaccination and medication with antimicrobial agents. Prudent use of antibiotics can be improved greatly by the determination of antibiotic susceptibility prior to the treatment. However, the conventional broth or agar microdilution is very labor-intensive and time-consuming method. Thus, there is an increasing need for rapid antimicrobial susceptibility tests in order to guide antibiotic therapy more effectively. The aim of this study was to develop mismatch amplification mutation assays (MAMAs) to detect resistance-associated mutations in M. synoviae. M. synoviae strains with previously determined minimal inhibitory concentrations (MICs) and whole genomes (n = 92) were used for target selection and assay specification. For the evaluation of the developed assays, 20 clinical samples and an additional 20 M. synoviae isolates derived from these specimens were also included in this study. MIC values of these 20 isolates were determined by broth microdilution method. Five MAMAs were designed to identify elevated MICs of fluoroquinolones, while three MAMAs were developed to detect decreased susceptibility to macrolides and lincomycin. The sensitivity of the MAMA tests varied between 10(2)−10(4) template copy number/reaction depending on the assay. Clinical samples showed identical genotype calls with the M. synoviae isolates derived from the corresponding specimens in each case. Supporting the results of conventional in vitro sensitivity tests, our approach provides a feasible tool for diagnostics. Rapidity, robustness and cost-effectiveness are powerful advantages of the developed assays. Supporting prudent antibiotic usage instead of empirical treatment, the use of this method can reduce significantly the economic impact of M. synoviae in the poultry industry and decrease bacterial resistance-related public health concerns.
format Online
Article
Text
id pubmed-7598480
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-75984802020-11-03 Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of Mycoplasma synoviae isolates Bekő, Katinka Kreizinger, Zsuzsa Yvon, Cécile Saller, Orsolya Catania, Salvatore Feberwee, Anneke Gyuranecz, Miklós PLoS One Research Article Mycoplasma synoviae infection occurs worldwide, leading to considerable economic losses in the chicken and turkey industry due to infectious synovitis, respiratory diseases and eggshell apex abnormalities. Control programs against M. synoviae infection are based on eradication, vaccination and medication with antimicrobial agents. Prudent use of antibiotics can be improved greatly by the determination of antibiotic susceptibility prior to the treatment. However, the conventional broth or agar microdilution is very labor-intensive and time-consuming method. Thus, there is an increasing need for rapid antimicrobial susceptibility tests in order to guide antibiotic therapy more effectively. The aim of this study was to develop mismatch amplification mutation assays (MAMAs) to detect resistance-associated mutations in M. synoviae. M. synoviae strains with previously determined minimal inhibitory concentrations (MICs) and whole genomes (n = 92) were used for target selection and assay specification. For the evaluation of the developed assays, 20 clinical samples and an additional 20 M. synoviae isolates derived from these specimens were also included in this study. MIC values of these 20 isolates were determined by broth microdilution method. Five MAMAs were designed to identify elevated MICs of fluoroquinolones, while three MAMAs were developed to detect decreased susceptibility to macrolides and lincomycin. The sensitivity of the MAMA tests varied between 10(2)−10(4) template copy number/reaction depending on the assay. Clinical samples showed identical genotype calls with the M. synoviae isolates derived from the corresponding specimens in each case. Supporting the results of conventional in vitro sensitivity tests, our approach provides a feasible tool for diagnostics. Rapidity, robustness and cost-effectiveness are powerful advantages of the developed assays. Supporting prudent antibiotic usage instead of empirical treatment, the use of this method can reduce significantly the economic impact of M. synoviae in the poultry industry and decrease bacterial resistance-related public health concerns. Public Library of Science 2020-10-30 /pmc/articles/PMC7598480/ /pubmed/33125410 http://dx.doi.org/10.1371/journal.pone.0241647 Text en © 2020 Bekő et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Bekő, Katinka
Kreizinger, Zsuzsa
Yvon, Cécile
Saller, Orsolya
Catania, Salvatore
Feberwee, Anneke
Gyuranecz, Miklós
Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of Mycoplasma synoviae isolates
title Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of Mycoplasma synoviae isolates
title_full Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of Mycoplasma synoviae isolates
title_fullStr Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of Mycoplasma synoviae isolates
title_full_unstemmed Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of Mycoplasma synoviae isolates
title_short Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of Mycoplasma synoviae isolates
title_sort development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of mycoplasma synoviae isolates
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598480/
https://www.ncbi.nlm.nih.gov/pubmed/33125410
http://dx.doi.org/10.1371/journal.pone.0241647
work_keys_str_mv AT bekokatinka developmentofmolecularassaysfortherapidandcosteffectivedeterminationoffluoroquinolonemacrolideandlincosamidesusceptibilityofmycoplasmasynoviaeisolates
AT kreizingerzsuzsa developmentofmolecularassaysfortherapidandcosteffectivedeterminationoffluoroquinolonemacrolideandlincosamidesusceptibilityofmycoplasmasynoviaeisolates
AT yvoncecile developmentofmolecularassaysfortherapidandcosteffectivedeterminationoffluoroquinolonemacrolideandlincosamidesusceptibilityofmycoplasmasynoviaeisolates
AT sallerorsolya developmentofmolecularassaysfortherapidandcosteffectivedeterminationoffluoroquinolonemacrolideandlincosamidesusceptibilityofmycoplasmasynoviaeisolates
AT cataniasalvatore developmentofmolecularassaysfortherapidandcosteffectivedeterminationoffluoroquinolonemacrolideandlincosamidesusceptibilityofmycoplasmasynoviaeisolates
AT feberweeanneke developmentofmolecularassaysfortherapidandcosteffectivedeterminationoffluoroquinolonemacrolideandlincosamidesusceptibilityofmycoplasmasynoviaeisolates
AT gyuraneczmiklos developmentofmolecularassaysfortherapidandcosteffectivedeterminationoffluoroquinolonemacrolideandlincosamidesusceptibilityofmycoplasmasynoviaeisolates